Contemporaneous studies in animal models demonstrated that dapagliflozin, combined with ticagrelor, a P2Y12 antagonist, had a synergistic effect on attenuating the activation of NLRP3 inflammasome through the AMPK/mTOR axis for improving the progression of DCM [114]. The gene discussed is NLRP3; the disease is familial dilated cardiomyopathy.